Analyzing web searches for axial spondyloarthritis in Germany: a novel approach to exploring interests and unmet needs.

Authors:
Berr K; Tizek L; Schielein MC; Welcker M; Knitza J and 2 more

Journal:
Rheumatol Int

Publication Year: 2023

DOI:
10.1007/s00296-023-05273-x

PMCID:
PMC10125933

PMID:
36640175

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Rheumatol Int

Abbreviation: Rheumatol Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthri…
Duruöz MT; Bodur H; Ataman Ş and 13 more (2024) - Transparency Score: 3/6
Trends in health care of patients with vasculitides, including giant cell arteritis, Takayasu arter…
Henes J; Richter JG; Thiele K and 3 more (2024) - Transparency Score: 3/6
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early diseas…
Sfikakis PP; Vassilopoulos D; Katsifis G and 19 more (2023) - Transparency Score: 3/6
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies rec…
Bae SS; Faure-Kumar E; Ferbas K and 7 more (2023) - Transparency Score: 3/6
Association between levels of serotonin, melatonin, cortisol and the clinical condition of patients…
Wróbel A; Szklarczyk J; Barańska I and 2 more (2023) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestLT received unrestricted research grants by Novartis Pharma GmbH and is currently employed by ViiV Healthcare GmbH. MCS is currently employed by Novartis Pharma GmbH. Ethical approvalThis study does not contain any human or animal experiments conducted by the authors. Conflict of interest LT received unrestricted research grants by Novartis Pharma GmbH and is currently employed by ViiV Healthcare GmbH. MCS is currently employed by Novartis Pharma GmbH."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL. Parts of this study were financially supported by an unrestricted research grant from Novartis Pharma GmbH."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025